DocWire News Editors

DocwireNews

Biosimilars were introduced to the market with the goal of reducing overall healthcare costs and increasing patients&rsquo; access to medications. Per guidelines from the U.S. Food and Drug Administration (FDA), biosimilars must have no significant differences from their reference products in terms of purity, safety, or efficacy, as demonstrated by clinical studies. Laws pertaining to record keeping and communicating with physicians and patients about biosimilar substitutions vary by state, but per the FDA, only biosimilars with interchangeable status can be switched with their reference product without notifying the provider.&nbsp;Biosimilars presumably cost less than their reference product, with estimates ranging from 10 percent to 30 percent in potential price cost reduction based on anticipated cost-savings models from small chemical molecule markets. However, specialty tiering could result in increased coinsurance rates. Various payment models, reimbursement schemes, and regulatory uncertainties may all affect just how much money patients save.&nbsp;Since questions remain about biosimilars despite their increasing popularity, hospital facility staffs should have a plan when considering biosimilars as additions or substitutions in both the inpatient and outpatient settings. They should start by comparing the currently used formulary biological drugs to the available biosimilars. Assuming the biosimilar and reference product are the same in terms of safety and efficacy, the review will be to evaluate potential cost-savings associated with the product. There are differences with drugs in the inpatient and outpatient settings: reimbursement for inpatient drugs tends to go through diagnosis-related groups&rsquo; bundled payments, while outpatient cost analysis should take into account variables such as private insurers and Medicaid, as well as unique pricing for 340b-eligible institutions. This year, Medicare implemented hospital outpatient prospective payment system (OPPS) changes, reducing part B reimbursement from average sales price (ASP) + 6 percent to ASP &ndash; 22.5 percent (rural sole community hospitals, children&rsquo;s hospitals, prospective payment system-exempt cancer hospitals, and medications with designated pass-through status are exempt). Hospital outpatient formularies may benefit from adding biosimilars to their list early on because innovative biologics&mdash;including biosimilars&mdash;receive pass-through status for two to three years.&nbsp;When considering adopting biosimilars in the outpatient setting, institutions must also consider varying state regulations and reimbursement rules for specific payers. To avoid negative reimbursement consequences, hospitals should review their contracts with their manufacturer and wholesaler groups to be aware of any rules pertaining to biosimilar interchanges. Medicare has tried to avert this problem by altering some of its biosimilar reimbursement schemes, but it is still important to consider utilization, average sales prices, and percent reimbursed from private and government insurances.&nbsp;If hospitals choose to add biosimilars to their formularies, it is up to the staff to stay up-to-date on their efficacy and safety, as well as those of their reference biologic products. A best practice would be to set electronic alerts linking biological reference agents with their biosimilar products in the event patients have had previous adverse reactions associated with either one.As more biosimilars make their way onto the market, it will be efficient in terms of time and cost for providers to have a biosimilar policy in place that considers the process for review, addition, and monitoring of biosimilar agents. Rather than individually reviewing each biosimilar upon FDA approval, a strategic policy for adding biosimilars to the formulary will save time and resources. The policy should also make clear individual state regulations for interchanging outpatient biosimilar products.&nbsp;<a href="http://hoparx.org/hopa-news/volume-15-issue-4-2018/practice-management">Read more at HOPA&nbsp;</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Biosimilar Formulary Evaluation: A Pharmacist’s Guide

Oncology

Biosimilars were introduced to the market with the goal of reducing overall healthcare costs and increasing patients’ access to medications. Per guidelines from the U.S. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe